Table 1 General characteristic of the included studies
Author/year | Country | DAA/PLA | Study | Follow-up | Outcomes | |||
|---|---|---|---|---|---|---|---|---|
Mean age (years) | No. of patients (n) | Female | BMI | |||||
Hu [24] | China | 58.2/59.3 | 110/98 | 68/58 | 25.8/25.6 | Prospective | NC | 5, 7, 10, 13, 14 |
Siljander [31] | USA | 65/64 | 1846/3162 | 1002/1799 | 27.4/30.2 | Retrospective | 3 | 1, 4, 5, 6, 7, 10, 12 |
Wu [32] | China | 49.67/48.21 | 24/23 | 9/10 | 22.16/23.32 | Retrospective | 15 | 1, 2, 3, 4, 13, 14, 15 |
Barrett [20] | USA | NC | 43/44 | NC | NC | RCT | 60 | 15, 17 |
Daas [33] | Netherlands | 74.8/72.1 | 41/26 | 33/22 | 27.6/28.1 | Retrospective | 12 | 17 |
Fleischman [34] | USA | 62.7/66.6 | 5465/2160 | 2815/1164 | 28.4/28.8 | Retrospective | 24 | 5, 7 |
Godoy-Monzon [25] | Argentina | 56.1/57.2 | 40/40 | 17/15 | NC | Prospective | 17.6 | 1,4,9,15 |
Triantafyllopoulos [35] | USA | 62.3/64.2 | 1182/18853 | 626/10126 | NC | Retrospective | 50 | 3 |
Lee [36] | Korea | 65.4/68.4 | 12/13 | NC | NC | Retrospective | 1.5 | 1, 2, 9 |
Rykov [21] | Netherlands | 62.8/60.2 | 23/23 | 15/12 | 29/29.3 | RCT | 1.5 | 1, 2, 3, 15, 17 |
Zhao [22] | China | 64.88/62.18 | 60/60 | 36/34 | 24.35/25.58 | RCT | 6 | 1, 2, 3, 4, 5, 13, 14, 15, 16 |
Fransen [37] | Netherlands | 64.2/62.6 | 45/38 | 30/24 | 25/27.6 | Retrospective | 12 | 1, 2, 3, 14 |
Jelsma [26] | Netherlands | 66.7/67.9 | 87/32 | 48/16 | 26.6/28 | Prospective | 6 | 3, 5, 6, 7, 8, 10, 11, 16, 17 |
Langlois [27] | France | 86/85 | 38/44 | 32/19 | 21/23 | Prospective | 1.5 | 1, 3, 7, 9 |
Amlie [38] | Norway | 67/66 | 421/421 | 291/268 | NC | Prospective | 36 | 7, 12 |
Barrett [23] | USA | 61.4/63.2 | 43/44 | 14/25 | 30.7/29.1 | RCT | 12 | 1,2,4,5,7,8,13,14,15,16,17 |
Nam [39] | USA | 66.76/66.86 | 110/110 | 71/65 | 28.3/27.4 | Retrospective | 6 | 13, 14 |
Spaans [40] | Netherlands | 69/68 | 46/46 | 22/32 | 25/29 | Retrospective | 12 | 1, 2, 3, 5, 7, 9, 11, 14 |